[go: up one dir, main page]

WO1998025594A3 - Lamotrigine in the treatment and prophylaxis of migraine - Google Patents

Lamotrigine in the treatment and prophylaxis of migraine Download PDF

Info

Publication number
WO1998025594A3
WO1998025594A3 PCT/EP1997/006971 EP9706971W WO9825594A3 WO 1998025594 A3 WO1998025594 A3 WO 1998025594A3 EP 9706971 W EP9706971 W EP 9706971W WO 9825594 A3 WO9825594 A3 WO 9825594A3
Authority
WO
WIPO (PCT)
Prior art keywords
lamotrigine
migraine
prophylaxis
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/006971
Other languages
French (fr)
Other versions
WO1998025594A2 (en
Inventor
John Morris Evans
Andrew Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to CA002274858A priority Critical patent/CA2274858A1/en
Priority to JP52623998A priority patent/JP2001510461A/en
Priority to EP97953793A priority patent/EP0948325A2/en
Publication of WO1998025594A2 publication Critical patent/WO1998025594A2/en
Publication of WO1998025594A3 publication Critical patent/WO1998025594A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating or preventing migraine in humans comprises administering to a patient in need thereof an effective amount of lamotrigine or a pharmaceutically acceptable salt thereof.
PCT/EP1997/006971 1996-12-12 1997-12-09 Lamotrigine in the treatment and prophylaxis of migraine Ceased WO1998025594A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002274858A CA2274858A1 (en) 1996-12-12 1997-12-09 Novel treatment
JP52623998A JP2001510461A (en) 1996-12-12 1997-12-09 Lamotrigine in the treatment and prevention of migraine
EP97953793A EP0948325A2 (en) 1996-12-12 1997-12-09 Lamotrigine in the treatment and prophylaxis of migraine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9625795.1A GB9625795D0 (en) 1996-12-12 1996-12-12 Novel treatment
GB9625795.1 1996-12-12

Publications (2)

Publication Number Publication Date
WO1998025594A2 WO1998025594A2 (en) 1998-06-18
WO1998025594A3 true WO1998025594A3 (en) 1998-09-17

Family

ID=10804309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/006971 Ceased WO1998025594A2 (en) 1996-12-12 1997-12-09 Lamotrigine in the treatment and prophylaxis of migraine

Country Status (5)

Country Link
EP (1) EP0948325A2 (en)
JP (1) JP2001510461A (en)
CA (1) CA2274858A1 (en)
GB (1) GB9625795D0 (en)
WO (1) WO1998025594A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040709A1 (en) * 2002-07-29 2005-04-13 Glaxo Group Ltd FORMULATION OF LAMOTRIGIN FOR LONG-TERM RELEASE AND USE OF THE SAME FOR PREPARATION
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459830A1 (en) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Pharmacologically active CNS compounds
EP0459829A1 (en) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Pharmacologically active CNS compounds
WO1993016700A1 (en) * 1992-02-19 1993-09-02 The Wellcome Foundation Limited Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and ×dema
WO1994018972A2 (en) * 1993-02-25 1994-09-01 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using n-(2,6-disubstituted aromatic)-n'-pyridinyl ureas and other anticonvulsant compounds
WO1997020827A1 (en) * 1995-12-05 1997-06-12 Laboratorios Del Dr. Esteve, S.A. Fluorophenyl-triazine and pyrimidine derivatives as compounds acting on the central nervous system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459830A1 (en) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Pharmacologically active CNS compounds
EP0459829A1 (en) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Pharmacologically active CNS compounds
WO1993016700A1 (en) * 1992-02-19 1993-09-02 The Wellcome Foundation Limited Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and ×dema
WO1994018972A2 (en) * 1993-02-25 1994-09-01 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using n-(2,6-disubstituted aromatic)-n'-pyridinyl ureas and other anticonvulsant compounds
WO1997020827A1 (en) * 1995-12-05 1997-06-12 Laboratorios Del Dr. Esteve, S.A. Fluorophenyl-triazine and pyrimidine derivatives as compounds acting on the central nervous system

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'ANDREA ET AL.: "Effectiveness of lamotrigine in the prophylaxis of migraine with aura. An open pilot study", J. NEUROL. SCI., vol. 150, no. suppl, September 1997 (1997-09-01), pages s239, XP002065865 *
STEINER ET AL.: "Lamotrigine versus placebo in the prophylaxis of migraine with aura", CEPHALALGIA, vol. 17, no. 2, April 1997 (1997-04-01), pages 109 - 112, XP002065866 *
STEINER ET AL.: "Safety data from a placebo-controlled trial of lamotrigine", INT. CONGR. SYMP., SER.- R SOC. MED., vol. 214, 1996, pages 31 - 35, XP002065864 *

Also Published As

Publication number Publication date
JP2001510461A (en) 2001-07-31
GB9625795D0 (en) 1997-01-29
CA2274858A1 (en) 1998-06-18
WO1998025594A2 (en) 1998-06-18
EP0948325A2 (en) 1999-10-13

Similar Documents

Publication Publication Date Title
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
AU6915396A (en) Multiple sclerosis treatment
CA2189658A1 (en) Controlled-Release Dosage Forms of Azithromycin
PL310476A1 (en) Application of lamotrigin in treating neuro-aids diseases
CA2130805A1 (en) Use of mannose phosphates for the treatment of fibrotic disorders
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
HU9503625D0 (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
EP0744176A3 (en) Methods for inhibiting bone loss
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
GB2277265B (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema
WO1998025594A3 (en) Lamotrigine in the treatment and prophylaxis of migraine
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
AU6502194A (en) Oestriol-containing hormonal agent for the prophylaxis and treatment of arterial conditions in humans, method of preparing it and its use
IL126158A0 (en) Method for treating substance abuse
WO1994004159A3 (en) Treatment of cancer with azt and alkylating or intercalating agents
MY118982A (en) Method of reducing tissue damage associated with ischemia
WO1999065511A3 (en) Composition and method for treatment of pseudomonas infection
AU1554295A (en) Method for treatment and prevention of disease in animals
GB2318057A (en) Treatment of nocturnal polyuria using an ace inhibitor in combination with a diuretic
AUPM533894A0 (en) Prophylactic and therapeutic treatment of pathogenic infections in plants and animals
IT1285552B1 (en) DEVICE AND METHOD FOR THE TREATMENT OF PARTS OF THE HUMAN BODY
AUPO372596A0 (en) Composition and method for the prevention and treatment of skin disorders
EP1712231A3 (en) Method for improving the pharmacokinetics of tipranavir

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2274858

Country of ref document: CA

Ref country code: CA

Ref document number: 2274858

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 526239

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997953793

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09319845

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997953793

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997953793

Country of ref document: EP